Trial Search Results

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Merck Sharp & Dohme Corp.

Stanford Investigator(s):

Intervention(s):

  • Drug: caspofungin acetate

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Clinical and Laboratory evidence of blood stream &/or systemic candida infections

Exclusion Criteria:

   - Possible candida contamination

   - Candida colonization (non invasive infection), urine, cardiac, bone or brain and
   prosthetic device infections

   - Acute or moderately severe liver disease

   - Abnormal liver function tests

   - Abnormal blood clotting for patients on blood thinners

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Joanna Schaenman
Not Recruiting